根據最近提交給美國證券交易委員會（SEC）的文件顯示，Zenas BioPharma 的一名內部人士購買了價值 1,067,200 美元的股票。

Update: -- Parex Resources Announcing Preliminary Q1 Results; Expects To generate FFO of US$114 million and FFO per share of $1.18

Parex Resources Announcing Preliminary Q1 Results; Expects To generate FFO of $114 million and FFO per share of $1.18

Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.